Solid Tumor Completed Phase 1 Trials for Lapatinib (DB01259)

Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)

IndicationStatusPhase
DBCOND0030180 (Solid Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00662636
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By SurgeryTreatment
NCT00389922
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid TumorsTreatment
NCT00807859
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerTreatment
NCT00984425
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid TumorsTreatment
NCT00495872
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid TumorTreatment